Zalicus is a biopharmaceutical company engaged in discovering and developing novel treatments for patients suffering with pain. The company’s portfolio of proprietary clinical-stage product candidates has entered into various revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Applying its expertise in discovering and developing selective ion channel modulators, as well as its combination high throughput screening capabilities, the company discovers innovative therapeutics for itself and its collaborators. For more information, visit the company’s Web site at www.zalicus.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: